Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery (GOSAFE)

7. maj 2019 opdateret af: AUSL ROMAGNA

GOSAFE Study Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery An International Prospective Audit to Evaluate Postoperative Functional Outcomes and Quality of Life After Cancer Surgery in Geriatric Patients

Multicenter, international, prospective, observational study, designed to evaluate the postoperative results in terms of quality of life and functional recovery of elderly patients after major cancer surgery.

The global expected duration of the study is 3 years, during which cancer patients over 70 years old undergoing major surgery will be evaluated before and after the surgical intervention, at 30 days, 3- and 6-months follow-up. The study is non-for-profit. Given the observational nature of the study, the original treatment plan, as designed by each individual recruiting centre, will not be altered or affected by the study inclusion. Inclusion in the study does not imply any deviation from the current standard of practice, and no change is expected to the perioperative treatment at any point. Patients will be only asked to complete simple screening/assessment tests.

Studieoversigt

Status

Ukendt

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

GOSAFE study is a prospective international collaborative high-quality registry aiming to gain knowledge about postoperative outcomes in older cancer patients with a particular emphasis on QoL and FR. The target is to obtain meaningful data to assist clinicians in tailoring the care, avoiding under/over-treatment, providing robust data to identify new strategies to improve functional outcomes in older cancer patients.

Recruiting centers will collect data prospectively. Recruited patients will be followed for 6 months after their surgery.

The original treatment plan, as designed by each individual recruiting centre, will not be altered or affected by the study inclusion.

Centers should ensure that they would make every possible effort to include all consecutive eligible patients during the study period and provide completeness of data entry to ensure a 'real-life' study.

Patients both gender, both gender, aged ≥70, affected by solid malignancy undergoing elective major surgical procedures with curative or palliative intent are eligible.

Inclusion in the study does not imply any deviation from the current standard of practice, and no change is expected to the perioperative treatment at any point. Patients will be only asked to complete simple screening/assessment tests.

For every eligible patient, demographic data will be collected at baseline followed by a fast preoperative functional assessment. Data regarding surgical procedures and perioperative measures will be collected. Complications will be reported and graded according to Clavien-Dindo Classification. Three- and six-month follow up data will be collected after surgery within a range of 2 weeks from the due date.

The Full Analysis Set (FAS) consists of all registered patients. The primary endpoint will be measured for all registered subjects who fulfill preoperative and postoperative EQ VAS. Demographic and baseline patient characteristics will be summarized for all patients in the FAS. Continuous-scaled variables (e.g., age) will be summarized with means, medians, standard deviations, quartiles, and minimum and maximum values. Categorical variables (e.g., sex) will be summarized using patient counts and percentages. Study endpoints and variables will be evaluated using descriptive statistics, and the key figures of the distributions will be presented in tables. Univariate analyses will allow for a first overview of potentially influential factors.

Multiple linear regression models will be performed in order to evaluate predictors of functional recovery at 3 months and 6 months after surgery.

Exploratory subgroup analyses will be performed. Missing values will be replaced and estimated using multiple imputations. Furthermore, sensitivity analysis will be executed using complete-case analysis.

A sample size of 265 patients who completed pre and postoperative EQ VAS questionnaires will have a 90% power to detect an effect size of 0,2 between pre and post surgery ,using a paired t-test with a 0,05 two sided significance level.

Given a potential loss to follow-up (about 10%), uncompleted questionnaires (about 10%) and postoperative mortality (about 15%), the sample size will be increased to 350-400 patients (see ref 18 and 19).

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1004

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

      • Liverpool, Det Forenede Kongerige
        • Dept. of Surgical Oncology - St. Helens Hospital of Liverpool
      • Manchester, Det Forenede Kongerige
        • Manchester Royal Infirmary, University of Manchester
    • Florida
      • Weston, Florida, Forenede Stater, 33331
        • Cleveland Clinic Florida
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater, 02115
        • Brigham and Women's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
        • University of Pennsylvenia Medical Center
    • Rhode Island
      • Providence, Rhode Island, Forenede Stater, 02908
        • Roger William Medical Centre
      • Thessaloníki, Grækenland, 54248
        • Medical School, Aristotle University of Thessaloniki
      • Groningen, Holland
        • Groeningen University Hospital
      • Petah Tikva, Israel, 4592500
        • Rabin Medical Center
      • Milano, Italien, 20162
        • Ospedale Niguarda
      • Piacenza, Italien, 29121
        • Ospedale di Piacenza
      • Vercelli, Italien, 13100
        • Clinica S. Rita
    • Forli-Cesena
      • Forlì, Forli-Cesena, Italien, 47121
        • Ospedale di Forlì
    • Lazio
      • Roma, Lazio, Italien, 00100
        • Ospedale S. Andrea
    • Liguria
      • Genova, Liguria, Italien, 16121
        • IRCCS Ospedale S. Martino Genova, Chirurgia Generale ad indirizzo oncologico
      • Genova, Liguria, Italien, 16121
        • IRCCS Ospedale S. Martino Genova, Clinica Chirurgica 1
    • Milano
      • Rozzano, Milano, Italien, 20089
        • Humanitas
    • Monza E Brianza
      • Desio, Monza E Brianza, Italien, 20039
        • Ospedale di Desio
    • Perugia
      • Spoleto, Perugia, Italien, 06049
        • Ospedale S. Matteo degli Infermi
    • Puglia
      • Bari, Puglia, Italien, 70121
        • IstitutoTumori Giovanni Paolo II
    • Ravenna
      • Faenza, Ravenna, Italien, 48018
        • General Surgery Unit
    • Rimini
      • Riccione, Rimini, Italien, 47838
        • Ospedale di Riccione
      • Oslo, Norge
        • Institute of clinical medicine
      • Kraków, Polen
        • Jagiellonian University Medical College
      • Lisbon, Portugal
        • General Surgery dept,Hospital Sao Francisco Xavier (CHLO)
      • Santiago do Cacém, Portugal, 7500
        • Unidade Local de Saúde do Litoral Alentejano (ULSLA)
      • Alicante, Spanien, 03001
        • Universidad Miguel Hernández. Elche. Alicante
      • Valencia, Spanien, 46700
        • Hospital Universitario y Politecnico La Fe

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

70 år og ældre (Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Centers should ensure that they would make every possible effort to include all consecutive eligible patients during the study period and provide completeness of data entry to ensure a 'real-life' study.

Beskrivelse

Inclusion Criteria:

  1. All consecutive patients, both gender, aged ≥70
  2. Patients affected by solid malignancy
  3. Patients undergoing elective major surgical procedures with curative or palliative intent (all major procedures including any resection, for any cancer, via any operative approach, open, laparoscopic, robotic, etc…)
  4. Informed consent obtainment

Exclusion Criteria:

  1. Patients undergoing emergent/urgent surgical procedures
  2. Planned hospital stay less than 48 hours

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
Group 1
Elderly patiences with solid malignancy
Quality of Life and Functional recovery questionnaires

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Quality of Life (QoL)
Tidsramme: 6 months
To evaluate the effects of surgery on patients' life perception by comparing pre- and post-operative QoL in elderly patients undergoing major surgery for solid malignancies using a self-reported Quality of Life assessment tool
6 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Functional recovery (FR)
Tidsramme: 6 months
To evaluate FR in terms of nutritional status, restoration of daily activities and cognitive status
6 months
Morbidity
Tidsramme: 6 months
To evaluate 3 and 6 months postoperative morbidity
6 months
Mortality
Tidsramme: 6 months
To evaluate 3 and 6 months postoperative mortality
6 months
Prognostic factors
Tidsramme: 6 months
To obtain prognostic factors for postoperative functional recovery which will assist in the treatment planning /intervention of future elderly patients who are offered surgery for cancer
6 months

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

27. februar 2017

Primær færdiggørelse (Forventet)

1. februar 2020

Studieafslutning (Forventet)

1. februar 2020

Datoer for studieregistrering

Først indsendt

20. september 2017

Først indsendt, der opfyldte QC-kriterier

27. september 2017

Først opslået (Faktiske)

3. oktober 2017

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

9. maj 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. maj 2019

Sidst verificeret

1. maj 2019

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • GOSAFE

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

3
Abonner